A dose reduction of Erleada may result in fewer skin-related side effects for men with advanced prostate cancer but only for those with a smaller body size, research showed.
Reduced doses of apalutamide did not significantly decrease rates of skin-related adverse effects vs full-dose apalutamide in patients with advanced prostate cancer.